Coya Therapeutics Inc (COYA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.76+4.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · COYA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress enrollment and data readout for COYA 302 in ALS and initiate Phase 2 study in FTD, with key milestones in 2H 2026 and topline data expected in 1Q 2027.
Stated as a priority in 2 of last 2 quarters. Management reported enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned with topline data expected in 1Q 2027, and plans to initiate a Phase 2 study in FTD in 2H 2026. The trajectory matches management's stated timeline and progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, on track to complete enrollment this year and report topline data in 1Q 2027.”
“The ALSTARS trial is now in full recruitment mode, and we maintain our guidance for a 1Q 2027 topline readout.”
Ensure sufficient cash and cash equivalents to fund operations through the Phase 2 ALSTARS topline data readout and beyond into late 2027.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents declined from $50.7 million in 2026-Q1 to $43.2 million in 2026-Q2 but remain sufficient to fund operations past the Phase 2 ALSTARS topline data readout and into the second half of 2027. The trajectory is delivering on the cash runway guidance.
“As of June 30, 2026, Coya had cash and cash equivalents of $43.2 million, sufficient to fund operations past Phase 2 ALSTARS topline data and into second half of 2027.”
“As of March 31, 2026, Coya had cash and cash equivalents of $50.7 million.”
Obtain FDA Fast Track designation, expand trial inclusion criteria, and publish scientific data supporting COYA 302's mechanism and clinical potential.
Stated as a priority in 2 of last 2 quarters. Management secured FDA Fast Track designation for COYA 302 in ALS, amended the ALSTARS trial protocol to broaden patient eligibility, and published scientific data supporting the drug's mechanism. These regulatory and clinical development milestones show delivering progress.
“Received FDA Fast Track Designation for COYA 302 for ALS; published data supporting mechanistic rationale; ALSTARS trial protocol amended to broaden patient population.”
“FDA granted Fast Track Designation to COYA 302 for ALS on March 11, 2026; IND accepted for FTD; protocol amended to remove exclusion criteria to increase enrollment.”
Appoint experienced independent director to support transition from clinical to commercial stage.
Newly stated in 2026-Q2. The company appointed Mark H. Pavao as an independent director with commercial expertise to support the transition toward commercialization. This is a strategic talent addition aligned with management's stated direction.
Focus on surpassing earnings expectations as demonstrated by recent performance.
Over the trailing year it converted 0.50x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.